Home › NDC Lookup › Ingredients › Econazole Nitrate › 45802-0466-35
Econazole Nitrate 10 mg/g Cream — NDC 45802-0466-35 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Econazole Nitrate 10 mg/g Cream — NDC 45802-466-35 (Billing 45802-0466-35)

by Padagis Israel Pharmaceuticals Ltd · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of Econazole Nitrate 10 mg/g Cream from Padagis Israel Pharmaceuticals Ltd, marketed since Aug 2006 and currently FDA-listed; retail pharmacies pay about $0.3973 per g (NADAC).

NDC 45802-0466-35
🏷️ FDA NDC (as labeled) 45802-466-35 billing pads the product segment with a zero
This package
Contains15 g in 1 tube Cost per g$0.3973 NADAC Per package$5.96 / 15 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.6047/unit · Part D plans $0.4803/unit — full pricing hub ↓
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 45802-466-35 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
45802 labeler · 466 product · 35 package
Package marketed since
Dec 21, 2006
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 4580246635 8
Medicaid fills, this package
7,050 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-466-35
Product NDC 45802-466
11-digit billing NDC 45802046635
NCPDP billing unit GM — per gram (weight)
RxCUI 857366
UNII H438WYN10E
Application # ANDA076479
SPL Set ID 3acc5e03-0339-4b23-945d-641746e81923
Established class (EPC) Azole Antifungal
Chemical class Azoles
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2006-08-08
Route TOPICAL
Dosage form CREAM
Substance ECONAZOLE NITRATE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90154035103705
GPI class Econazole Nitrate
GCN Seq No 007371
GCN 30430
HICL code 016904
Ingredient (HICL) Econazole Nitrate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 84:04.08.08
AHFS class Azoles (Skin And Mucous Membrane)
FDB label name ECONAZOLE NITRATE 1% CREAM
FDB brand name Econazole Nitrate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007371
  • GCN: 30430
  • GPI-14 (Medi-Span): 90154035103705
  • HICL (First Databank): 016904
  • AHFS class code: 84:04.08.08
  • RxCUI (RxNorm): 857366
Why two NDCs? The FDA registers this code as 45802-466-35 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0466-35. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Azole Antifungal class.

Pharmacologic class Azole Antifungal
Drug family (ATC) Imidazole and triazole derivatives, Imidazole derivatives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ECONAZOLE NITRATE 1% CREAM Ingredient Econazole Nitrate
📗 Our plain-language guide HelloPharmacist
  • It treats fungal skin infections. The foam is for athlete's foot between the toes in people 12 and older. The cream is used for athlete's foot, ringworm of the groin and body, tine...
  • The cream goes on once a day for most tinea infections and twice a day for skin yeast infections. The foam is used once daily for athlete's foot. Follow your prescriber's direction...
  • Keep going even if you feel better early. The cream is typically used for two weeks for yeast infections, groin and body ringworm, and one month for athlete's foot. This lowers the...
  • Side effects are uncommon. In foam trials, skin reactions where it was applied happened in less than 1% of people, about the same as the foam without medicine.
📖 Read our full Econazole Topical guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Econazole Nitrate — tap one for details:

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.397 $5.96 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.6047 $9.07 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.4803 $7.20 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.509 $0.340
▲ Up 14% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
45802-0466-11 45802-466-11 1 TUBE in 1 CARTON / 30 g in 1 TUBE $0.3509 / g $10.53 2006-11-10 — Active
45802-0466-35 You're viewing this 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.3973 / g $5.96 2006-12-21 — Active
45802-0466-53 45802-466-53 Main listing 1 TUBE in 1 CARTON / 85 g in 1 TUBE $0.2116 / g $17.99 2006-08-08 — Active

Per g, this pack runs about 88% above the cheapest pack (NDC 45802-0466-53, $0.2116 vs $0.3973 NADAC).

This pack accounts for about 34% of this product's recent Medicaid fills; the largest share goes to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of Econazole Nitrate 10 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Econazole Nitrate 10 mg/gthis 45802-0466-35 Padagis 1 tube $0.397 AB Availability likely —
Econazole Nitrate 10 mg/g 51672-1303-01 Sun 1 tube $0.397 AB Availability likely —
Econazole Nitrate 10 mg/g 59651-0945-14 Aurobindo 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 63629-8645-01 Bryant 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 63629-8646-01 Bryant 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 63629-8647-01 Bryant 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 68788-8170-03 Preferred 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 68788-8174-01 Preferred 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 68788-8884-03 Preferred 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 72162-1410-04 Bryant 1 tube — AB FDA listed —
Econazole Nitrate 10 mg/g 21922-0111-04 Encube 1 tube — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2006
On the market since
Aug 2006
📍
2026
Currently FDA-listed
20 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Econazole Topical inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 8SKN0B0MIM
    Benzoic acid is a naturally occurring organic acid used as a preservative in medicines and foods. It helps prevent bacterial and fungal growth to extend shelf life and maintain product stability.
  • UNII REK4960K2U
    Butylated hydroxyanisole is a synthetic preservative that prevents oils and fats in medicines from spoiling or becoming rancid. It keeps the medicine stable and extends its shelf life.
  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII 0240V77G50
    A synthetic compound made by combining polyethylene glycol with oleic acid (a natural fatty acid). It acts as an emulsifier and solubilizer to help mix water and oil-based ingredients in the medicine.
  • UNII 3EW5AXE5X5
    A synthetic surfactant derived from polyethylene glycol and stearic acid. It helps mix oil and water-based ingredients together and improves how the medicine dissolves and is absorbed in the body.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS ISRAEL PHARMACEUTICALS LTD
FDA applicationANDA076479 (ANDA)
Labeler code45802
First marketedAug 2006
Product typeHuman Prescription Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 52 words ▾

INDICATIONS AND USAGE Econazole Nitrate Cream is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.

⏱️ Dosage and Administration 122 words ▾

DOSAGE AND ADMINISTRATION Sufficient Econazole Nitrate Cream, 1% should be applied to cover affected areas once daily in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor, and twice daily (morning and evening) in patients with cutaneous candidiasis. Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence.

If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

⛔ Contraindications 17 words ▾

CONTRAINDICATIONS Econazole Nitrate Cream is contraindicated in individuals who have shown hypersensitivity to any of its ingredients.

⚠️ Warnings 9 words ▾

WARNINGS Econazole Nitrate Cream is not for ophthalmic use.

🤒 Adverse Reactions 43 words ▾

ADVERSE REACTIONS During clinical trials, approximately 3% of patients treated with econazole nitrate cream, 1% reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging, and erythema. One case of pruritic rash has also been reported.

🔄 Drug Interactions 73 words ▾

Drug Interactions Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulation effect. Most cases reported product application with use under occlusion, genital application, or application to large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

🤰 Pregnancy 108 words ▾

Pregnancy Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

Econazole nitrate should be used in the first trimester of pregnancy only when the physician considers it essential to the welfare of the patient. The drug should be used during the second and third trimesters of pregnancy only if clearly needed.

🆘 Overdosage 36 words ▾

OVERDOSE Overdosage of econazole nitrate in humans has not been reported to date. In mice, rats, guinea pigs and dogs, the oral LD 50 values were found to be 462, 668, 272, and >160 mg/kg, respectively.

🧬 Clinical Pharmacology 164 words ▾

CLINICAL PHARMACOLOGY After topical application to the skin of normal subjects, systemic absorption of econazole nitrate is extremely low. Although most of the applied drug remains on the skin surface, drug concentrations were found in the stratum corneum which, by far, exceeded the minimum inhibitory concentration for dermatophytes . Inhibitory concentrations were achieved in the epidermis and as deep as the middle region of the dermis.

Less than 1% of the applied dose was recovered in the urine and feces. Microbiology: Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Dermatophytes Yeasts Epidermophyton floccosum Trichophyton mentagrophytes Candida albicans Microsporum audouini Trichophyton rubrum Malassezia furfur Microsporum canis Trichophyton tonsurans Microsporum gypseum Econazole nitrate exhibits broad-spectrum antifungal activity against the following organisms in vitro , but the clinical significance of these data is unknown .

Dermatophytes Yeasts Trichophyton verrucosum Candida guillermondii Candida parapsilosis Candida tropicalis

📦 How Supplied / Storage and Handling 74 words ▾

HOW SUPPLIED Econazole Nitrate Cream, 1% is available as follows: 15 g tube (NDC 45802- 466 -35) 30 g tube (NDC 45802- 466 -11) 85 g tube (NDC 45802- 466 -53) Store at 20-25ºC (68-77ºF) [see USP Controlled Room Temperature]. To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch for voluntary reporting of adverse reactions. Manufactured by Padagis ® Yeruham, Israel www.padagis.com Rev 11-23 71D00 RC PH2

📋 Description 56 words ▾

DESCRIPTION Econazole Nitrate Cream contains the antifungal agent, econazole nitrate 1%, in a water-miscible base consisting of benzoic acid, butylated hydroxyanisole, mineral oil, peglicol 5 oleate, pegoxol-7 stearate, and purified water. The white to off-white soft cream is for topical use only. Chemically, econazole nitrate is 1-[2-{(4-chlorophenyl)methoxy}-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole mononitrate.

Its structure is as follows: Structural Formula Image

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued. For external use only. Avoid introduction of Econazole Nitrate Cream into the eyes.

Drug Interactions Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulation effect. Most cases reported product application with use under occlusion, genital application, or application to large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

Carcinogenesis, mutagenesis, impairment of fertility Long-term animal studies to determine carcinogenic potential have not been performed. Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation. Intravaginal administration in humans has not shown prolonged gestation or other adverse reproductive effects attributable to econazole nitrate therapy.

Pregnancy Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

Econazole nitrate should be used in the first trimester of pregnancy only when the physician considers it essential to the welfare of the patient. The drug should be used during the second and third trimesters of pregnancy only if clearly needed. Nursing Mothers It is not known whether econazole nitrate is excreted in human milk.

Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups. Also, in lactating rats receiving large oral doses (40 or 80 times the human dermal dose), there was a reduction in post partum viability of pups and survival to weaning; however, at these high doses, maternal toxicity was present and may have been a contributing factor. Caution should be exercised when econazole nitrate is administered to a nursing woman.

Geriatric Use Clinical studies of econazole nitrate cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

🍼 Nursing Mothers 95 words ▾

Nursing Mothers It is not known whether econazole nitrate is excreted in human milk. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups. Also, in lactating rats receiving large oral doses (40 or 80 times the human dermal dose), there was a reduction in post partum viability of pups and survival to weaning; however, at these high doses, maternal toxicity was present and may have been a contributing factor.

Caution should be exercised when econazole nitrate is administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 49 words ▾

Carcinogenesis, mutagenesis, impairment of fertility Long-term animal studies to determine carcinogenic potential have not been performed. Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation. Intravaginal administration in humans has not shown prolonged gestation or other adverse reproductive effects attributable to econazole nitrate therapy.

📄 Package Label / Principal Display Panel 51 words ▾

Principal Display Panel NDC 45802-466-35 Rx Only Econazole Nitrate Cream, 1% For Topical Use Only. Not For Ophthalmic Use. NET WT 15 g The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation. carton image serialization-template.jpg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
7.1K
Units reimbursed last 4 qtrs
243.3K
Gross reimbursed last 4 qtrs
$147.1K
Avg / prescription
$20.86
Avg / unit
$0.6047
Latest quarter Q1 2026
1.5KRx
Medicaid pays / g
$0.6047
gross reimbursed
vs
NADAC / g
$0.3973
acquisition cost
=
Spread
+$0.2074
+52% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
53% FFS 47% MCO
Fee-for-service · 3,766 Rx Managed care · 3,284 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 2,625 units · 45.8 per 100k residents MN Wisconsin: no data reported WI Michigan: 5,670 units · 56.5 per 100k residents MI New York: 11,580 units · 59.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 11,625 units · 92.6 per 100k residents IL Indiana: no data reported IN Ohio: 20,700 units · 176 per 100k residents OH Pennsylvania: 16,230 units · 125 per 100k residents PA New Jersey: 12,375 units · 133 per 100k residents NJ Massachusetts: 2,490 units · 35.6 per 100k residents MA California: 121,055 units · 311 per 100k residents CA Utah: 285 units · 8.3 per 100k residents UT Colorado: 1,035 units · 17.6 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 135 units · 3.0 per 100k residents KY West Virginia: 1,320 units · 74.6 per 100k residents WV Virginia: no data reported VA Maryland: 6,235 units · 101 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: 1,185 units · 40.3 per 100k residents KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: 1,080 units · 105 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: 3,945 units · 77.2 per 100k residents AL Georgia: 315 units · 2.9 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 7,980 units · 26.2 per 100k residents TX Florida: 15,405 units · 68.1 per 100k residents FL
Units reimbursed · per 100k residents
2.9311
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 311 /100k
2 Ohio 176 /100k
3 New Jersey 133 /100k
4 Pennsylvania 125 /100k
5 Delaware 105 /100k
6 Maryland 101 /100k
7 Illinois 92.6 /100k
8 Alabama 77.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube45802-0466-53 7,815 Rx · $228,448
1 tube this page45802-0466-35 7,050 Rx · $147,095
1 tube45802-0466-11 6,134 Rx · $132,289
Drug total (last 4 qtrs): 20,999 Rx · 1,164,621 units · $507,832 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Econazole Nitrate — the program that covers self-administered drugs. 3 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Econazole Nitrate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$1.65M
Claims incl. refills
37.4K
Beneficiaries
29.7K
Spend / beneficiary
$55.48
Spend / claim
$44.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.